Compare Cassava Sciences Inc (FLNA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Charles Schwab Corporation Common Stock — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Charles Schwab Corporation Common Stock trades at $102.96 (market cap $178.77B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 3364.1× Cassava Sciences Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SCHW | |
|---|---|---|
Market Cap | $53.14M | $178.77B |
Sector | Health | Financials |
52-Week High | $4.64 | $107.21 |
52-Week Low | $1.09 | $85.35 |
Enterprise Value | -$33.43M | — |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Charles Schwab (SCHW) trades at $101.10, down 1.25% today, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential near-term overbought conditions. Recent financial performance demonstrates robust revenue growth to $23.92 billion in 2025 and net income margin expansion to 37.99%, supported by strong trading activity and asset management fees.
The outlook remains positive with analyst consensus pointing to 25.9% upside potential to $123.71. Key catalysts include continued earnings growth and strong retail trading activity, while risks involve interest rate sensitivity and market volatility. With 58% of analysts maintaining buy ratings and improving cash flow trends, SCHW presents a compelling investment case for growth-oriented investors despite current valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
